EUVIMEDEUVIMED entdecken
Open Access

Antimicrobial-Resistant Infections in Hospitalized Patients

Hannah Wolford, Natalie L McCarthy, James Baggs, Kelly M Hatfield, Alexander Maillis, Babatunde Olubajo, Jonathan Bishop, Mia Ferretti, Michael R Craig, Shelley S Magill, L Clifford McDonald, Dawn M Sievert und 4 weitere

JAMA Network Open · 14.03.2025 · 8 (3) · e2462059

DOI: 10.1001/jamanetworkopen.2024.62059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 14.03.2025. Verfasst von Hannah Wolford und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. Hauptthemen laut MEDLINE: Hospitalization, Cross Infection, Bacterial Infections. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Antimicrobial resistance is a major public health problem in the US. Estimating national rates of antimicrobial-resistant infections commonly associated with health care can aid in targeted public health efforts.

Objective

To determine the national incidence rates of 6 pathogens over time: methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus spp (VRE), extended-spectrum cephalosporin-resistant Escherichia coli and Klebsiella spp (excluding Klebsiella aerogenes) (ESCR-EK), carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant Acinetobacter spp (CRAsp), and multidrug-resistant (MDR) Pseudomonas aeruginosa . Design, Setting, and Participants This cohort study used data from 2012 to 2022 on inpatient hospitalizations, clinical cultures, and facility-level characteristics. Hospital-months were included in the dynamic cohort if the hospital reported at least 1 culture with microbial growth accompanied by antimicrobial susceptibility testing (AST) results in the month. Data from the PINC-AI and Becton Dickinson Insights databases were used, and cases were defined as incident nonsurveillance cultures yielding an organism of interest with sufficient AST results for a phenotype of interest. Data were collected from January 2012 to December 2022 and analyzed from April 2023 to June 2024. Exposure Inpatient hospitalizations with a discharge date in an included hospital month. Main Outcomes and Measures National annual antimicrobial-resistant cases per 10 000 hospitalizations were obtained using weights based on facility-level characteristics. Cases were defined as community-onset if collected on or before day 3 of hospitalization and hospital-onset if obtained on day 4 or later.

Results

This study cohort included 332 to 606 hospitals per year between 2012 to 2022 and 7 158 139 cultures. Antimicrobial-resistant pathogens accounted for an estimated 569 749 (95% CI, 475 949-663 548) cases and 179.6 (95% CI, 163.1-196.1) cases per 10 000 hospitalizations in 2022. Of these cases, 77% (437 657; 95% CI, 364 529-510 785) were community-onset and 23% (132 092; 95% CI, 108 241-155 943) were hospital-onset. MRSA (44% [251 854; 95% CI, 209 558-294 150]) and ESCR-EK (35% [200 884; 95% CI, 163 692-238 077]) made up the largest proportions of total infections in 2022, respectively. Rates of hospital-onset MRSA, VRE, CRE, CRAsp, and MDR P aeruginosa had periods of decline from 2012 to 2019; however, all pathogens experienced an increase in hospital-onset rates in 2020 and 2021. Community-onset ESCR-EK rates increased from 2012 to 2022, while community-onset rates of MRSA, VRE, and MDR P aeruginosa declined. Conclusions and Relevance While antimicrobial resistance rates have experienced uneven declines in the US from 2012 to 2022, the burden of resistance remains substantial. These findings suggest that more effective strategies to reduce antimicrobial resistance are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HospitalizationCross InfectionBacterial InfectionsHumansFemaleMaleMiddle AgedUnited StatesAgedIncidenceMethicillin-Resistant Staphylococcus aureusCohort StudiesMicrobial Sensitivity TestsAnti-Bacterial AgentsAdultDrug Resistance, Multiple, BacterialVancomycin-Resistant Enterococci

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.

Zitieren

APA

Wolford, H., McCarthy, N. L., Baggs, J., Hatfield, K. M., Maillis, A., Olubajo, B., Bishop, J., Ferretti, M., Craig, M. R., Magill, S. S., McDonald, L. C., Sievert, D. M., Spalding Walters, M., Jernigan, J. A., Lutgring, J. D., & Reddy, S. C. (2025). Antimicrobial-Resistant Infections in Hospitalized Patients. JAMA Network Open, 8(3), e2462059. https://doi.org/10.1001/jamanetworkopen.2024.62059

Vancouver

Wolford H, McCarthy NL, Baggs J, Hatfield KM, Maillis A, Olubajo B, et al. Antimicrobial-Resistant Infections in Hospitalized Patients. JAMA Network Open. 2025;8(3):e2462059. doi:10.1001/jamanetworkopen.2024.62059

BibTeX
@article{Wolford2025,
  author = {Wolford, Hannah and McCarthy, Natalie L and Baggs, James and Hatfield, Kelly M and Maillis, Alexander and Olubajo, Babatunde and Bishop, Jonathan and Ferretti, Mia and Craig, Michael R and Magill, Shelley S and McDonald, L Clifford and Sievert, Dawn M and Spalding Walters, Maroya and Jernigan, John A and Lutgring, Joseph D and Reddy, Sujan C},
  title = {Antimicrobial-Resistant Infections in Hospitalized Patients},
  journal = {JAMA Network Open},
  year = {2025},
  volume = {8},
  number = {3},
  pages = {e2462059},
  doi = {10.1001/jamanetworkopen.2024.62059}
}
Kostenlos starten →